NCT01664975View on ClinicalTrials.gov

Treatment of Peripheral T-cell Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

GDPT regimen

GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.

DRUG

CHOP regimen

CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.

Trial Locations (1)

450052

Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

Zhengzhou University

OTHER

lead

Mingzhi Zhang

OTHER

NCT01664975 - Treatment of Peripheral T-cell Lymphoma | Biotech Hunter | Biotech Hunter